Keywords
Clopidogrel
Ticagrelor
Percutaneous Coronary Intervention
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Discuss the most effective use of antiplatelet aggregation after percutaneous coronary intervention. Methods: The methodological approach of this work proposes a compilation of bibliographic research with a qualitative approach and descriptive character through an integrative review of the literature in the PubMed and Virtual Health Library databases. The descriptors used were “Platelet Aggregation Inhibitors” and “Clopidogrel” and “Ticagrelor” and “Percutaneous Coronary Intervention”. Inclusion criteria were clinical trial, controlled clinical trial and randomized controlled trial, published in English, Portuguese and Spanish, between 2017 and August 2022. The drugs covered were clopidogrel, ticagrelor, aspirin and prasugrel. Results: There were a total of nine articles concluding a greater effectiveness of clopidogrel in relation to ticagrelor, and in only one ticagrelor was superior. In addition, the effectiveness of prasugrel in cases of major coronary adverse events was also seen compared to clopidogrel. Final considerations: Thus, it can be emphasized that ticagrelor is not the most effective drug to be used as a standard antiplatelet agent in PCI, as stated in the guideline, and should give way to clopidogrel, except in specific special cases, which may also very for the use of prasugrel.
References
AHLUWALIA K e BHANWRA S. Antiplatelet therapy: present status and its future directions. International Journal of Basic & Clinical Pharmacology, 2014; 3(2).
ALAAMRI S e DALBHI SA. Risk of bleeding with ticagrelor in elderly patients over 75 years old: A systematic review and meta-analysis. Medicine, 2021; e27398–e27398.
BUTT JH, et al. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections. Eur Heart J Cardiovasc Pharmacother, 2022; 13–19.
EIKELBOOM JW, et al. Antiplatelet Drugs. Chest, 2012; 141(2): e89S-e119S.
FERES F, et al. Diretriz da sociedade brasileira de cardiologia e da sociedade brasileira de hemodinâmica e cardiologia intervencionista sobre intervenção coronária percutânea. Arquivos Brasileiros de Cardiologia, 2017; 109(1).
HAHN J-Y, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet, 2018; 391(10127): 1274–1284.
KIM CJ, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. The Lancet, 2021; 398(10308): 1305–1316.
KOO B-K, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet, 2021; 397(10293): 2487–2496.
LI J, et al. Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. Curr Med Res Opin, 2020; 36(11): 1739–1745.
LI X-Y, et al. Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes. Clin Cardiol, 2018; 41(11): 1446–1454.
LI Y-S, et al. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Br J Clin Pharmacol, 2022; 145–154.
LINDER M e ANDERSEN M. Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in Sweden. Pharmacoepidemiol Drug Saf, 2022; 235–246.
MOON H, et al. Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome. Health Qual Life Outcomes, 2021; 242–242.
PAN Y, et al. Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review. BMC Cardiovasc Disord, 2022; 40–40.
PARK D-W, et al. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. Circulation, 2019; 140(23): 1865–1877.
PEREIRA NL, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA, 2020; 324(8): 761–771.
RODRIGUEZ-ARIAS JJ, et al. Long-Term Vascular Function in CTO Recanalization: A Randomized Clinical Trial of Ticagrelor vs. Clopidogrel. Cardiovasc Revasc Med, 2022; 61–67.
SHAHID I, et al. Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis. Drugs Aging, 2021; 1003–1016.
SIBBING D, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, 2017; 390(10104): 1747–1757.
SILVAIN J, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet, 2020; 396(10264):1737–1744.
SILVERTHORN D. Fisiologia Humana: Uma Abordagem Integrada, 7ª Edição, Artmed, 2017.
TURGEON RD, et al. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Intern Med, 2020; 180(3): 420–428.
VRANCKX P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, 2018; 392(10151): 940–949.
WALLENTIN L, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2009; 361(11):1045–1057.
YING L, et al. Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on‐treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)‐2 Trial. Br J Haematol, 2022; 196(2): 424–432.